Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease
- PMID: 23178979
- DOI: 10.1016/j.jhep.2012.11.015
Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease
Abstract
Background & aims: Non-alcoholic fatty liver disease (NAFLD) is associated with a twofold greater risk of developing cardiovascular disease. Despite this, little is known about the effect of NAFLD upon cardiac function, limiting our ability to identify therapeutic strategies. This study aimed to address this by defining the effect of NAFLD on cardiac function, structure, and metabolism.
Methods: Nineteen adults with NAFLD were age-, sex-, and BMI-matched to healthy controls without liver or metabolic disease. Cardiac structure and function were assessed using high-resolution cardiac MRI and tagging at 3.0 T. High-energy phosphate metabolism was assessed using (31)P-magnetic resonance spectroscopy to measure the PCr/ATP ratio.
Results: Adults with NAFLD had significantly thicker left ventricular walls at systole (14 ± 3 vs. 12 ± 2 mm; p <0.01) and diastole (8 ± 1 vs. 7 ± 1 mm; p <0.01) than those without fatty liver and showed decreased longitudinal shortening (14 ± 3 vs. 17 ± 3%; p <0.01). The eccentricity ratio was significantly higher in the NAFLD group (1.1 ± 0.2 vs. 0.9 ± 0.2 g/ml; p <0.01) indicating concentric remodelling. Peak whole wall strain was higher in the NAFLD group (19 ± 2 vs. 17 ± 3%; p <0.01), as was peak endocardial strain (28 ± 4 vs. 22 ± 5%; p <0.01). Cardiac metabolism, measured by PCr/ATP ratio, was not altered in NAFLD (1.8 ± 0.3 vs. 1.9 ± 0.3; p=0.36).
Conclusions: Significant changes in cardiac structure and function are evident in adults with NAFLD in the apparent absence of metabolic changes or overt cardiac disease. Clinicians should continue to explore therapies to improve cardiac function as a means to modify the excess risk of cardiovascular disease associated with NAFLD.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Similar articles
-
[Research advances in the impact of nonalcoholic fatty liver disease on cardiac structure and function].Zhonghua Gan Zang Bing Za Zhi. 2016 Jun;24(6):461-4. doi: 10.3760/cma.j.issn.1007-3418.2016.06.015. Zhonghua Gan Zang Bing Za Zhi. 2016. PMID: 27465954 Review. Chinese.
-
Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver disease and associate with glycemic control.Cardiovasc Diabetol. 2015 Feb 13;14:23. doi: 10.1186/s12933-015-0187-2. Cardiovasc Diabetol. 2015. PMID: 25849783 Free PMC article.
-
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.World J Gastroenterol. 2014 Feb 21;20(7):1724-45. doi: 10.3748/wjg.v20.i7.1724. World J Gastroenterol. 2014. PMID: 24587651 Free PMC article. Review.
-
Left atrial deformation parameters in patients with non-alcoholic fatty liver disease: a 2D speckle tracking imaging study.Clin Sci (Lond). 2014 Feb;126(4):297-304. doi: 10.1042/CS20130298. Clin Sci (Lond). 2014. PMID: 23947743
-
Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment.J Clin Gastroenterol. 2006 Nov-Dec;40(10):949-55. doi: 10.1097/01.mcg.0000225668.53673.e6. J Clin Gastroenterol. 2006. PMID: 17063117
Cited by
-
How non-alcoholic fatty liver disease and cirrhosis affect the heart.Hepatol Int. 2023 Dec;17(6):1333-1349. doi: 10.1007/s12072-023-10590-1. Epub 2023 Sep 28. Hepatol Int. 2023. PMID: 37770804 Review.
-
Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial.BMC Gastroenterol. 2023 Sep 23;23(1):327. doi: 10.1186/s12876-023-02948-4. BMC Gastroenterol. 2023. PMID: 37742004 Free PMC article. Clinical Trial.
-
Correlation analysis of the abdominal visceral fat area with the structure and function of the heart and liver in obesity: a prospective magnetic resonance imaging study.Cardiovasc Diabetol. 2023 Aug 10;22(1):206. doi: 10.1186/s12933-023-01926-0. Cardiovasc Diabetol. 2023. PMID: 37563637 Free PMC article.
-
Predictive value of the Framingham steatosis index for cardiovascular risk: a nationwide population-based cohort study.Front Cardiovasc Med. 2023 Jul 18;10:1163052. doi: 10.3389/fcvm.2023.1163052. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37534274 Free PMC article.
-
Loss of hepatic PPARα in mice causes hypertension and cardiovascular disease.Am J Physiol Regul Integr Comp Physiol. 2023 Jul 1;325(1):R81-R95. doi: 10.1152/ajpregu.00057.2023. Epub 2023 May 22. Am J Physiol Regul Integr Comp Physiol. 2023. PMID: 37212551 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical